The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain

• Status: Completed
• Trial end date: 2017-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will test whether treatment with N-acetyl-L-cysteine (NAC) is safe and decreases pain in patients with chronic neuropathic pain. The investigators hypothesize that NAC will be a useful adjunct to opioid treatment in chronic neuropathic pain.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Virginia Commonwealth University
• Treatments: Acetylcysteine; N-monoacetylcystine

Criteria

Inclusion Criteria:

• 18-65 years old

• non-cancer neuropathic pain

• stable dose of opioids for pain

• using breakthrough pain meds

• still with persistent pain per VAS

Exclusion Criteria:

• pregnant or nursing

• serious medical or psychiatric illness (including uncontrolled hypertension)

• active stomach ulcer, history or seizures or asthma

• breakthrough pain meds other than opioids

• using illicit drugs